CGM for type 1 diabetes
Intensive insulin therapy is a 24/7 task. Continuous monitoring shows every curve and every alert.
What it is
Type 1 diabetes is autoimmune destruction of pancreatic β-cells; the patient depends on exogenous insulin for life. It accounts for 5–10% of all diabetes. CGM has moved from "nice-to-have" to standard of care for intensive insulin therapy, per ADA 2024 standards.
Clinical targets per Battelino 2019
TIR
Time in range 3.9–10.0 mmol/L > 70%. Each +10% TIR ≈ −0.8% HbA1c.
TBR
Time below range < 4% (< 3.9) and < 1% (< 3.0). Hypos count less than time spent in hypo.
TAR
Time above range < 25% (> 10.0) and < 5% (> 13.9).
GMI
Glucose Management Indicator — estimated HbA1c from 14 days of CGM data; compared with the lab value.
CV
Glucose variability coefficient ≤ 36%. Above that signals instability and hypo risk.
Management principles with CGM
Data-driven basal/bolus
Basal is calibrated against overnight and inter-meal trends; bolus against post-prandial peaks. Without CGM, calibration is blind.
Alerts as therapy
Low predictive alert 20 minutes before hypo, high alert 30 minutes before excursion. Enable on intensive insulin.
AGP report every 2 weeks
Ambulatory Glucose Profile — a standardised summary chart. Adjust therapy from the report rather than from memory.
Joint review with the clinician
Cloud AGP access for the clinician — a 10-minute visit instead of 40 minutes parsing paper diaries.
Where Syai fits in this scenario
14 days without replacement covers two full AGP reporting cycles without calibration breaks. Bluetooth + the child / parent / patient's own phone — no separate reader. Configurable high/low/urgent low alerts. MARD < 10% meets requirements for insulin-dosing CGM use.
Syai default
Standard T1D use — continuous wear, replace every 14 days.
Studies
Clinical targets for continuous glucose monitoring data interpretation
Battelino T. et al. · Diabetes Care · 2019
ADA Standards of Care 2024 — diabetes technology chapter
American Diabetes Association · Diabetes Care Suppl. 1 · 2024
On requestCGM in adults with type 1 diabetes — meta-analysis of RCTs
Maiorino M.I. et al. · Diabetes Care · 2020
On request
Further reading
More on the manufacturer's site
Syai Health maintains a detailed topic page with clinical cases. Opens in a new tab.